AbbVie, Xilio to Develop Novel Tumor-Activated Immunotherapies

 

• Collaboration will combine AbbVie’s oncology expertise and Xilio’s proprietary tumor-activation technology to develop novel immunotherapies, including masked T-cell engagers
• Xilio to host investor conference call and webcast today at 8:30 am EST

Under the terms of the agreement, Xilio will receive $52.0 million in total upfront payments, including a $10.0M equity investment, and will be eligible to receive up to approximately $2.1 billion in total contingent payments for option-related fees and milestones plus tiered royalties.

Xilio Investor Conference Call Information

Xilio will host a conference call and webcast today at 8:30 am EST. Viewers can access the webcast by using this link. Listeners who require dial-in access should register here to receive a unique PIN and information to join the call. Listeners are encouraged to join at least 15 minutes prior to the scheduled start time. The webcast will also be accessible under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com. A replay of the webcast will be archived on the website for 30 days following the presentation.

https://www.globenewswire.com/news-release/2025/02/12/3024949/0/en/AbbVie-and-Xilio-Therapeutics-Announce-Collaboration-and-Option-Agreement-to-Develop-Novel-Tumor-Activated-Immunotherapies.html